2005 Food and Drug Administration Healthcare Safety 
European Pharmaceutical Review
JULY 13, 2023
1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. 3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.
Expert insights. Personalized for you.
83 
Let's personalize your content